Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 11/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 11/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27191020 | 0.83 | P2RX3 (0.40) | NPC1ALDH1A1RAB9AP2RX3P2RX2 | |
| SCHEMBL21625515 | 0.82 | ALDH1A1 (0.43) | NPC1ALDH1A1RAB9AP2RX3P2RX2 | |
| SCHEMBL20681216 | 0.81 | GAA (0.33) | NPC1ALDH1A1RAB9AP2RX3P2RX2 | |
| SCHEMBL30154939 | 0.81 | POLB (0.40) | NPC1ALDH1A1RAB9AP2RX3P2RX2 | |
| SCHEMBL21542868 | 0.81 | POLB (0.40) | NPC1ALDH1A1RAB9AP2RX3P2RX2 | |
| SCHEMBL28536032 | 0.81 | P2RX3 (0.34) | NPC1ALDH1A1RAB9AP2RX3P2RX2 | |
| SCHEMBL21625497 | 0.80 | KCNK3 (0.32) | — | |
| SCHEMBL21625513 | 0.78 | CDK2 (0.33) | — | |
| SCHEMBL23234577 | 0.77 | GABRA1 (0.33) | P2RX3P2RX2POLBGAAGFER | |
| SCHEMBL23762609 | 0.75 | SMPD3 (0.31) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3823974-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-3823726-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | F. Hoffmann-La Roche SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-112513048-A | Sulfonylimide compounds as inhibitors of interleukin-1 activity | 豪夫迈·罗氏有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-112437683-A | Sulfonylurea compounds useful as inhibitors of interleukin-1 activity | 豪夫迈·罗氏有限公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020018975-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020018970-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020018970-A1 | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | NPC1 1576/4885ALDH1A1 1225/4885RAB9A 2388/4885 |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | NPC1 750/4885ALDH1A1 1315/4885RAB9A 2544/4885 |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | NPC1 1576/4885ALDH1A1 1225/4885RAB9A 2388/4885 |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | IL1A, IL18, IL1B | NPC1 1576/4885ALDH1A1 1225/4885RAB9A 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.